A药品名称: B药品名称: B与A对换
 药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
A药品
B药品
详细
Cinolazepam
Cortivazol
The risk or severity of adverse effects can be increased when Cortivazol is combined with Hydrocortisone butyrate.
Cinolazepam
Acteoside
The risk or severity of adverse effects can be increased when Acteoside is combined with Hydrocortisone butyrate.
Cinolazepam
Deoxyspergualin
The risk or severity of adverse effects can be increased when Deoxyspergualin is combined with Hydrocortisone butyrate.
Cinolazepam
Doxifluridine
The risk or severity of adverse effects can be increased when Doxifluridine is combined with Hydrocortisone butyrate.
Cinolazepam
Trofosfamide
The risk or severity of adverse effects can be increased when Trofosfamide is combined with Hydrocortisone butyrate.
Cinolazepam
Cepeginterferon alfa-2B
The risk or severity of adverse effects can be increased when Cepeginterferon alfa-2B is combined with Hydrocortisone butyrate.
Cinolazepam
Gusperimus
The risk or severity of adverse effects can be increased when Gusperimus is combined with Hydrocortisone butyrate.
Cinolazepam
Mizoribine
The risk or severity of adverse effects can be increased when Mizoribine is combined with Hydrocortisone butyrate.
Cinolazepam
Ocrelizumab
The risk or severity of adverse effects can be increased when Ocrelizumab is combined with Hydrocortisone butyrate.
Cinolazepam
Deflazacort
The risk or severity of adverse effects can be increased when Deflazacort is combined with Hydrocortisone butyrate.
Cinolazepam
Guselkumab
The risk or severity of adverse effects can be increased when Guselkumab is combined with Hydrocortisone butyrate.
Cinolazepam
Sirukumab
The risk or severity of adverse effects can be increased when Sirukumab is combined with Hydrocortisone butyrate.
Cinolazepam
Brodalumab
The risk or severity of adverse effects can be increased when Brodalumab is combined with Hydrocortisone butyrate.
Cinolazepam
Sarilumab
The risk or severity of adverse effects can be increased when Sarilumab is combined with Hydrocortisone butyrate.
Cinolazepam
Peficitinib
The risk or severity of adverse effects can be increased when Peficitinib is combined with Hydrocortisone butyrate.
Cinolazepam
Voclosporin
The risk or severity of adverse effects can be increased when Voclosporin is combined with Hydrocortisone butyrate.
Cinolazepam
Pirarubicin
The risk or severity of adverse effects can be increased when Pirarubicin is combined with Hydrocortisone butyrate.
Cinolazepam
Ravulizumab
The risk or severity of adverse effects can be increased when Ravulizumab is combined with Hydrocortisone butyrate.
Cinolazepam
Ixekizumab
The risk or severity of adverse effects can be increased when Ixekizumab is combined with Hydrocortisone butyrate.
Cinolazepam
Melengestrol
The risk or severity of adverse effects can be increased when Melengestrol is combined with Hydrocortisone butyrate.
免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究  客服热线:0575-83552251 / 13754370441  QQ客服:药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证:浙B2-20220931 互联网药品信息服务资格证书编号:(浙)-经营性2023-0215 浙公网安备:330683240604819103159
 医药代理商群1:药药网药品采购交流医药代理商群2:药药网药品采购交流2医药代理商群3:药药网药品采购交流3